Murepavadin antibiotics target a completely new path of killing bacteria.
For the first time in 40 years, people have created a new class of antibiotics. The announcement was made by Swiss pharmaceutical company Polyphor AG, after their scientists successfully tested an antibiotic called Murepavadin (POL7080).
In addition, Murepavadin is also the first human antibiotic to target directly to multidrug-resistant viruses. In the trial, it was used to treat pneumonia patients, caused by a green pus bacillus (Pseudomonas aeruginosa).
Green latex bacilli ranked second, among the top 12 most dangerous viruses warned by the World Health Organization (WHO) last February.
WHY IN THE 40 YEARS, WE CANNOT DEVELOP AN MORE NEW LIVING ENERGY?
As we all know, the development of new antibiotics has stalled for decades. The reason for antibiotic production is becoming less profitable for pharmaceutical companies. It is estimated that a single antibiotic sold only generates a profit of 1 per thousand to 1 per cent compared to cancer treatments.
And when the market is not fertile, most pharmaceutical companies are not interested in studying new antibiotics. They all want to turn to developing drugs for chronic patients, such as diabetes, heart disease and cancer, diseases that can be cashed out.
Therefore, in the past 30-40 years, no new antibiotic class has been developed successfully. That story became much worse, as we entered the current global antibiotic resistance crisis.
Thanks in large part to the boom of antibiotics from the 40-70s of the last century, people have accumulated about 20 classes of antibiotics, divided into more than 100 types. However, after Alexander Fleming found the first antibiotic, he soon predicted that the bacteria would win every day.
In fact, the bacteria that develop a new generation of them only take 20 minutes. With a favorable condition, a bacterium can become resistant 1,000 times in just 2 weeks.
That is why, we increasingly have to witness many cases of patients dying because bacteria are resistant to all existing human drugs.
In the current context, sometimes we have no longer any antibiotics to treat patients infected with all drugs. Finding one or more new antibiotics is called an urgent task by the World Health Organization (WHO).
It is estimated that antibiotic resistance is killing about 700,000 people annually in the world. If the situation does not improve, the number could increase to 10 million by 2050.
With over $ 2.3 million in funding from the Wellcome Trust (a British biomedical research charity) Polyphor AG has promoted their research on a completely new class of antibiotics within the last 40 years. pass a clinical trial.
In the results reported at the European Society for Clinical and Infectious Diseases conference in Austria, scientists say new antibiotics have a success rate of over 91%.
Known as OMPTA (Outer Membrane Protein Targeting Antibiotics), this antibiotic targets a completely new pathway to kill bacteria. The first drug in the OMPTA antibiotic class is being tested by Polyphor as Murepavadin (POL7080).
Murepavadin antibiotics target infection caused by green pus bacillus (Pseudomonas aeruginosa), one of the 12 most powerful drug-resistant viruses newly published by WHO. Green pus bacillus usually causes lung infections and brings the death rate of patients up to 50%.
In Phase I clinical trials, researchers at Polyphor monitored 12 patients using Murepavadin antibiotics. After 28 days, only 1 patient died and 11 patients were cured.
Speaking at the conference, research leader Professor San Antonio Torres said: Murepavadin’s presentation of a positive result in clinical trials provided hope for us, in managing and treating the disease group. danger related to green pus bacilli.
“Green pus bacillus represents a worrying threat, for patients in hospitals who are most vulnerable. They include special care patients who have weakened immune systems such as cancer patients, severe burns, babies … “Dr. Ignacio Martin-loeches, from Trinity University, Ireland like more.
“Current treatment options are reaching the limit, so this antibiotic class is really necessary,”.
In fact, multidrug-resistant blue bacilli has become a global problem. And Murepavadin antibiotic is the first antibiotic developed to specifically address this problem of multidrug-resistant bacteria.
At the present time, the clinical trial for Murepavadin has reached phase II. The researchers concluded that this new antibiotic is within an acceptable range of safety and tolerability. It is expected that by the end of 2017, Murepavadin antibiotics will advance to a Phase III clinical trial, which is the final test before the drug is marketed.
Representing the research team at Polyphor, Dr Glenn Dale said happily: “Today’s discovery shows that our Murepavidin dosage could be a promising new antibiotic. This year, we hope Murepavadin will advance to phase III of clinical trials, and complete other necessary steps to bring it to reach patients. ”